In the current trading session, CRISPR Therapeutics AG’s (CRSP) stock is trading at the price of $57.05, a fall of -4.26% over last night’s close. So, the stock is trading at a price that is -19.79% less than its 52-week high of $71.13 and 89.91% better than its 52-week low of $30.04.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CRSP’s SMA-200 is $44.59.
It is also essential to consider CRSP stock ratios like the price-to-sales ratio, which is 129.49 for the last year.CRSP’s price to book ratio for the most recent quarter was 2.95, resulting in an 2.86 price to cash per share for the period.
How does CRISPR Therapeutics AG (CRSP) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
CRISPR Therapeutics AG (CRSP): Earnings History
If we examine CRISPR Therapeutics AG’s recent earnings history, in the last quarter ended on 6/30/2025, it posted adjusted earnings per share of -$1.29, slashing the consensus of -$1.4. In other words, it beat the consensus by $0.11, resulting in a 7.81% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2025, the stock recorded adjusted earnings per share of -$1.29 in contrast with the Outlook of -$1.4. That was a difference of $0.11 and a surprise of 7.81%.
CRISPR Therapeutics AG (NASDAQ: CRSP) Ownership Details
I will give a breakdown of the key shareholders in CRISPR Therapeutics AG (CRSP). Recent figures show that the company’s insiders hold 1.69% of shares. A total of 535 institutional investors hold shares in the company, making 76.18% of its stock and 77.48% of its float.
Jun 30, 2025 , it was reported that the Company’s largest institutional holder is ARK Investment Management, LLC holding total of 10.18 shares that make 11.79% of the company’s total number of shares and are currently priced at 581.43 million.
The securities firm Capital International Investors holds 6.07 shares of CRSP, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 7.03% , and the holding percentage of shares is valued at 346.78 million.
An overview of CRISPR Therapeutics AG’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests CRISPR Therapeutics AG (CRSP) traded 3,819,803 shares per day, with a moving average of $60.00 and price change of +2.14. With the moving average of $50.04 and a price change of +19.43, about 3,409,507 shares changed hands on average over the past 50 days. Finally, CRSP’s 100-day average volume is 2,738,729 shares, alongside a moving average of $43.82 and a price change of +13.47.
